Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation.
The efficacy of liposomal FK506 was compared between a canine liver transplantation model and a canine kidney transplantation model. The present study revealed that liposomal FK506 increased immunosuppressive efficacy of FK506 in liver transplantation but decreased in kidney transplantation. Because liposomal FK506 increased FK506 levels in the liver and spleen, and decreased FK506 levels in the kidney, it was suggested that enhanced immunosuppressive efficacy in liver transplantation should be attributed to the local immunosuppressive effects in the hepatic allograft rather than effective suppression of splenocyte activity.
Ko
S
S
First Department of Surgery, Nara Medical University, Kashihara, Japan.
Nakajima
Y
Y
Kanehiro
H
H
Horikawa
M
M
Yoshimura
A
A
Kido
K
K
Taki
J
J
Aomatsu
Y
Y
Kin
T
T
Yagura
K
K
Ohyama
T
T
Ohashi
K
K
Yamada
T
T
Nakano
H
H
D000818:Animals; D004285:Dogs; D004337:Drug Carriers; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology; D006085:Graft Survival / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008081:Liposomes; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D016559:Tacrolimus / Q000008:administration & dosage* / Q000627:therapeutic use; D014184:Transplantation, Homologous
D004337:Drug Carriers; D007166:Immunosuppressive Agents; D008081:Liposomes; D016559:Tacrolimus